Travere Therapeutics, Inc. Company profile
Travere Therapeutics (TVTX) is a US-based biopharmaceutical company that identifies, develops and delivers life-changing therapies to people suffering from rare diseases. The firm is headquartered in San Diego, California.
The company currently has four approved commercial therapies: Chenodal (chenodiol), Cholbam (cholic acid), Thiola (tiopronin), and Thiola EC (tiopronin) delayed-release tablets.
The rare diseases for which the company currently offers therapies are Peroxisomal Biogenesis Disorder-Zellweger Spectrum Disorder (PBD-ZSD), Cerebrotendinous Xanthomatosis (CTX), Focal Segmental Glomerulosclerosis (FSGS), IgA Nephropathy (IgAN), Classical Homocystinuria (HCU), Cystinuria, Bile Acid Synthesis Disorders (BASD), N-Glycanase 1 (NGLY1) Deficiency, and Alagille Syndrome (ALGS).
Travere Therapeutics shares trade on the NASDAQ Stock Exchange under the ticker symbol TVTX. The company was founded as Retrophin Inc. in February 2011 and became public in December 2012.As of August 2022, Travere Therapeutics does not pay a dividend.
You can follow the ups and downs of the Travere Therapeutics stock price at Capital.com. Always stay on top of the latest price developments with our live TVTX stock price chart.
Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)